CytomX Therapeutics Announces Pricing of $250 Million Offering of Common Stock and Pre-Funded Warrants
CytomX Therapeutics, Inc. (CTMX)
Last cytomx therapeutics, inc. earnings: 11/7 04:09 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.cytomx.com
Company Research
Source: GlobeNewswire
SOUTH SAN FRANCISCO, Calif., March 17, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a leader in the field of masked, conditionally activated biologics, today announced the pricing of an underwritten public offering of 45,990,567 shares of its common stock at a price to the public of $5.30 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase 1,179,245 shares of common stock. The gross proceeds to CytomX from the offering are expected to be $250 million, before deducting underwriting discounts and commissions and estimated offering expenses. In addition, CytomX granted the underwriters a 30-day option to purchase up to an additional 7,075,471 shares of its common stock at the public offering price, less underwriting discounts and commissions. The closing of the offering is expected to occur on March 19, 2026, subject to customary closing conditions. All of the shares of common stock and pre-funded warrants are being sold by
Show less
Read more
Impact Snapshot
Event Time:
CTMX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CTMX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CTMX alerts
High impacting CytomX Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
CTMX
News
- CytomX Therapeutics (CTMX) was downgraded by <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a> from "hold (c-)" to "sell (d)".MarketBeat
- CytomX Therapeutics (CTMX) had its price target raised by Barclays PLC from $10.00 to $16.00. They now have an "overweight" rating on the stock.MarketBeat
- CytomX Therapeutics (CTMX) had its "buy" rating reaffirmed by Jefferies Financial Group Inc..MarketBeat
- CytomX Therapeutics: Great News, But Early Data Do Not Quite Justify This Price Level [Seeking Alpha]Seeking Alpha
- CytomX Therapeutics (CTMX) had its price target raised by Guggenheim from $10.00 to $15.00. They now have a "buy" rating on the stock.MarketBeat
CTMX
Earnings
- 3/16/26 - Miss
CTMX
Sec Filings
- 3/19/26 - Form 4
- 3/19/26 - Form 4
- 3/19/26 - Form 4
- CTMX's page on the SEC website